SCHEMBL14181086

SCHEMBL14181086

Cc1cc(O)c(C(=O)CCc2ccc(Cl)cc2)c(OC2OC(CO)C(F)C(O)C2O)c1

nearest known ligand 0.67

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SLC5A1 P13866 16/20 0.67
▸ SLC5A2 P31639 12/20 0.67
▸ SLC28A3 Q9HAS3 2/20 0.61
▸ HPGD P15428 2/20 0.60
▸ HSD17B10 Q99714 2/20 0.60
▸ KDM4E B2RXH2 1/20 0.60
▸ CYP3A4 P08684 1/20 0.60
▸ MAPT P10636 1/20 0.60
▸ THRB P10828 1/20 0.60
▸ CYP2C9 P11712 1/20 0.60
▸ CYP2C19 P33261 1/20 0.60
▸ SLC28A2 O43868 1/20 0.60
▸ EPHX2 P34913 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12808046 0.94 SLC5A1 (0.70) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL12808059 0.93 SLC28A3 (0.71) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL12808053 0.92 SLC5A1 (0.71) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL12807953 0.91 SLC5A1 (0.72) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL12808045 0.88 SLC5A1 (0.68) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL12808039 0.85 SLC5A1 (0.86) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL16075091 0.84 SLC28A3 (0.85) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL12808160 0.84 SLC28A3 (0.85) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL13553029 0.83 SLC5A2 (0.72) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
SCHEMBL13553044 0.81 SLC28A3 (0.66) SLC5A1SLC5A2SLC28A3HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080108580-A1 NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-05-08 — — US disclosed
US-20080108580-A1 NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-05-08 — — US disclosed
US-7288528-B2 Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-10-30 — — US disclosed
US-7288528-B2 Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-10-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108580-A1 NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF SLC5A2, SLC5A1, UGGT1 SLC5A1 2/4885SLC5A2 1/4885SLC28A3 1031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback